Why the study?
Does recombinant human growth hormone reduce liver fat content in young adults with obesity and NAFLD?
Does recombinant human growth hormone reduce liver fat content in young adults with obesity and NAFLD?
Recombinant human growth hormone may reduce liver fat content in young adults with obesity and NAFLD, though larger studies are needed to confirm this effect.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for rhGH in obese young adults with NAFLD; larger trials needed before clinical adoption.
Data from this pilot study suggest that rhGH treatment in young adults with obesity and NAFLD may have benefits to reduce liver fat content, although larger studies are needed to confirm this effect.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: